Biogen Idec Multiple Sclerosis Pregnancy Exposure Registry
Phase of Trial: Phase IV
Latest Information Update: 23 Mar 2019
Price : $35 *
At a glance
- Drugs Dimethyl fumarate (Primary) ; Daclizumab; Peginterferon beta-1a
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms TEC-GISTRY
- Sponsors Biogen
- 12 Oct 2018 Interim results (data cut off: 15 Dec, 2017; n=199) presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 17 Sep 2018 Planned End Date changed from 15 Jun 2028 to 31 May 2028.
- 17 Sep 2018 Planned primary completion date changed from 15 Jun 2028 to 31 May 2028.